News articles about Express Scripts (NASDAQ:ESRX) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Express Scripts earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.9273271698518 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news stories that may have impacted Accern Sentiment’s scoring:
NASDAQ ESRX traded down $1.30 during trading hours on Friday, hitting $67.88. The company’s stock had a trading volume of 3,195,176 shares, compared to its average volume of 5,700,227. Express Scripts has a 12 month low of $55.80 and a 12 month high of $85.07. The company has a market capitalization of $38,116.72, a price-to-earnings ratio of 9.56, a PEG ratio of 0.83 and a beta of 0.99. The company has a debt-to-equity ratio of 0.83, a quick ratio of 0.55 and a current ratio of 0.67.
Express Scripts (NASDAQ:ESRX) last announced its earnings results on Tuesday, February 27th. The company reported $2.16 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.09 by $0.07. The business had revenue of $25.38 billion for the quarter, compared to analysts’ expectations of $25.07 billion. Express Scripts had a return on equity of 25.19% and a net margin of 4.51%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm posted $1.88 earnings per share. equities analysts predict that Express Scripts will post 9.35 earnings per share for the current fiscal year.
Express Scripts declared that its Board of Directors has initiated a stock repurchase program on Monday, December 18th that permits the company to repurchase 45,000,000 outstanding shares. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are usually a sign that the company’s board believes its stock is undervalued.
ESRX has been the subject of several analyst reports. SunTrust Banks restated a “buy” rating and set a $95.00 price target on shares of Express Scripts in a report on Friday, January 12th. Zacks Investment Research downgraded Express Scripts from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 13th. Robert W. Baird upgraded Express Scripts from a “neutral” rating to an “outperform” rating and raised their price target for the company from $72.00 to $81.00 in a report on Friday, December 15th. William Blair downgraded Express Scripts from an “outperform” rating to a “market perform” rating in a report on Thursday, March 8th. Finally, Raymond James Financial reiterated a “sell” rating on shares of Express Scripts in a report on Friday, December 15th. Three research analysts have rated the stock with a sell rating, fourteen have issued a hold rating and five have given a buy rating to the company’s stock. Express Scripts has an average rating of “Hold” and a consensus target price of $81.97.
In other Express Scripts news, VP Everett Neville sold 4,895 shares of the firm’s stock in a transaction dated Thursday, March 1st. The stock was sold at an average price of $75.26, for a total value of $368,397.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, VP Glen D. Stettin sold 3,449 shares of the firm’s stock in a transaction dated Thursday, January 11th. The stock was sold at an average price of $81.00, for a total value of $279,369.00. Following the completion of the transaction, the vice president now directly owns 33,715 shares in the company, valued at $2,730,915. The disclosure for this sale can be found here. Insiders sold 28,233 shares of company stock worth $2,173,054 over the last three months. Insiders own 0.68% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Somewhat Favorable News Coverage Somewhat Unlikely to Affect Express Scripts (ESRX) Share Price” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/04/08/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-express-scripts-esrx-share-price.html.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.